{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:15:10Z","timestamp":1770992110784,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T00:00:00Z","timestamp":1210723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s00228-008-0487-5","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T12:03:05Z","timestamp":1210680185000},"page":"697-703","source":"Crossref","is-referenced-by-count":12,"title":["Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells"],"prefix":"10.1007","volume":"64","author":[{"given":"Yan-Gang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-De","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,14]]},"reference":[{"key":"487_CR1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2004.06.002","volume":"25","author":"MF Fromm","year":"2004","unstructured":"Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423\u2013429","journal-title":"Trends Pharmacol Sci"},{"key":"487_CR2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00406-006-0664-4","volume":"256","author":"E Martin","year":"2006","unstructured":"Martin E, Uhr M (2006) ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response. Eur Arch Psychiatry Clin Neurosci 256:294\u2013298","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"487_CR3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","volume":"36","author":"AH Schinkel","year":"1999","unstructured":"Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179\u2013194","journal-title":"Adv Drug Deliv Rev"},{"key":"487_CR4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pneurobio.2005.04.006","volume":"76","author":"W Loscher","year":"2005","unstructured":"Loscher W, Potschka H (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22\u201376","journal-title":"Prog Neurobiol"},{"key":"487_CR5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0378-4274(01)00304-6","volume":"120","author":"OV Tellingen","year":"2001","unstructured":"Tellingen OV (2001) The importance of drug-transporting P-glycoproteins in toxicology. Toxicol Lett 120:31\u201341","journal-title":"Toxicol Lett"},{"key":"487_CR6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0378-4274(02)00497-6","volume":"140\u2013141","author":"A Bodo","year":"2003","unstructured":"Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B (2003) The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140\u2013141:133\u2013143","journal-title":"Toxicol Lett"},{"key":"487_CR7","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","volume":"363","author":"KT Mueser","year":"2004","unstructured":"Mueser KT, McGurk SR (2004) Schizophrenia. Lancet 363:2063\u20132072","journal-title":"Lancet"},{"key":"487_CR8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2005.07.025","volume":"79","author":"R Tandon","year":"2005","unstructured":"Tandon R, Fleischhacker WW (2005) Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 79:145\u2013155","journal-title":"Schizophr Res"},{"key":"487_CR9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","volume":"56","author":"AA Ela El","year":"2004","unstructured":"El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P (2004) Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56:967\u2013975","journal-title":"J Pharm Pharmacol"},{"key":"487_CR10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.102.039255","volume":"303","author":"KM Mahar Doan","year":"2002","unstructured":"Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marked drugs. J Pharmacol Exp Ther 303:1029\u20131037","journal-title":"J Pharmacol Exp Ther"},{"key":"487_CR11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00023210-200115040-00006","volume":"15","author":"SV Onrust","year":"2001","unstructured":"Onrust SV, McClellan K (2001) Perospirone. CNS Drugs 15:329\u2013337","journal-title":"CNS Drugs"},{"key":"487_CR12","first-page":"121","volume":"3","author":"T Paulis De","year":"2002","unstructured":"De Paulis T (2002) Perospirone (Sumitomo Pharmaceuticals). Curr Opin Invest Drugs 3:121\u2013129","journal-title":"Curr Opin Invest Drugs"},{"key":"487_CR13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF01138479","volume":"128","author":"M Hanelt","year":"1994","unstructured":"Hanelt M, Gareis M, Kollarczik B (1994) Cytotoxicity of mycotoxin evaluated by the MTT cell-culture assay. Mycopathologia 128:167\u2013174","journal-title":"Mycopathologia"},{"key":"487_CR14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.critrevonc.2004.12.010","volume":"56","author":"N Aouali","year":"2005","unstructured":"Aouali N, Eddabra L, Macadr\u00e9 J, Morjani H (2005) Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol 56:61\u201370","journal-title":"Crit Rev Oncol Hematol"},{"key":"487_CR15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hup.720","volume":"20","author":"TB Ejsing","year":"2005","unstructured":"Ejsing TB, Pedersen AD, Linnet K (2005) P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol Clin Exp 20:493\u2013500","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"487_CR16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.pnpbp.2006.04.009","volume":"30","author":"T Araki","year":"2006","unstructured":"Araki T, Kasai K, Rogers MA, Kato N, Iwanami A (2006) The effect of perospirone on auditory P300 in schizophrenia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30:1083\u20131090","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"487_CR17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pnpbp.2005.10.015","volume":"30","author":"T Araki","year":"2006","unstructured":"Araki T, Yamasue H, Sumiyoshi T, Kuwabara H, Suga M, Iwanami A, Kato N, Kasai K (2006) Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog Neuropsychopharmacol Biol Psychiatry 30:204\u2013208","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"487_CR18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neulet.2004.03.079","volume":"364","author":"T Yoshino","year":"2004","unstructured":"Yoshino T, Nisijima K, Shioda K, Yui K, Katoh S (2004) Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increase in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neurosci Lett 364:16\u201321","journal-title":"Neurosci Lett"},{"key":"487_CR19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF03190869","volume":"28","author":"J Shimakura","year":"2003","unstructured":"Shimakura J, Tani N, Mizuno Y, Komuro S, Kanamaru H (2003) In vitro drug-drug interactions with perospirone and concomitantly administered drugs in human liver microsomes. Eur J Drug Metab Pharmacokinet 28:67\u201372","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"487_CR20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/bdd.432","volume":"26","author":"A Kitamura","year":"2005","unstructured":"Kitamura A, Mizuno Y, Natsui K, Yabuki M, Komuro S, Kanamaru H (2005) Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. Biopharm Drug Dispos 26:59\u201365","journal-title":"Biopharm Drug Dispos"},{"key":"487_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF03190868","volume":"28","author":"Y Mizuno","year":"2003","unstructured":"Mizuno Y, Tani N, Komuro S, Kanamaru H, Nakatsuka I (2003) In vitro metabolism of perospirone in rat, monkey and human liver microsomes. Eur J Drug Metab Pharmacokinet 28:59\u201365","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"487_CR22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/01.jcp.0000236659.93415.4a","volume":"26","author":"Y Sekine","year":"2006","unstructured":"Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Okada H, Minabe Y, Nakamura K, Suzuki K, Iwata Y, Tsuchiya KJ, Sugihara G, Mori N (2006) Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin-2 and D2 receptor occupancy in the living human brain. J Clin Psychopharmacol 26:531\u2013533","journal-title":"J Clin Psychopharmacol"},{"key":"487_CR23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00007691-200408000-00004","volume":"26","author":"N Yasui-Furukori","year":"2004","unstructured":"Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T (2004) Steady-state Pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit 26:361\u2013365","journal-title":"Ther Drug Monit"},{"key":"487_CR24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","volume":"46","author":"MC Mauri","year":"2007","unstructured":"Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR (2007) Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46:359\u2013388","journal-title":"Clin Pharmacokinet"},{"key":"487_CR25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-2007-972573","volume":"40","author":"M Gerlach","year":"2007","unstructured":"Gerlach M, H\u00fcnnerkopf R, Rothenh\u00f6fer S, Libal G, Burger R, Clement HW, Fegert JM, Wewetzer Ch, Mehler-Wex C (2007) Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 40:72\u201376","journal-title":"Pharmacopsychiatry"},{"key":"487_CR26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00007691-200404000-00012","volume":"26","author":"C Hiemke","year":"2004","unstructured":"Hiemke C, Dragicevic A, Gr\u00fcnder G, Hatter S, Sachse J, Vernaleken I, Muller MJ (2004) Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26:156\u2013160","journal-title":"Ther Drug Monit"},{"key":"487_CR27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0304-3835(99)00020-8","volume":"139","author":"D Szab\u00f3","year":"1999","unstructured":"Szab\u00f3 D, Szab\u00f3 G Jr, Ocsovszki I, Aszalos A, Moln\u00e1r J (1999) Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 139:115\u2013119","journal-title":"Cancer Lett"},{"key":"487_CR28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2710.2003.00487.x","volume":"28","author":"RB Wang","year":"2003","unstructured":"Wang RB, Kuo CL, Lien LL, Lien EJ (2003) Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28:203\u2013228","journal-title":"J Clin Pharm Ther"},{"key":"487_CR29","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.1073\/pnas.97.12.6775","volume":"97","author":"S Jin","year":"2000","unstructured":"Jin S, Gorfajn B, Faircloth G, Scotto KW (2000) Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 97:6775\u20136779","journal-title":"Proc Natl Acad Sci USA"},{"key":"487_CR30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-2952(02)01224-8","volume":"64","author":"S Anuchapreeda","year":"2002","unstructured":"Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573\u2013582","journal-title":"Biochem Pharmacol"},{"key":"487_CR31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2007.04.107","volume":"358","author":"ST Yu","year":"2007","unstructured":"Yu ST, Chen TM, Tseng SY, Chen YH (2007) Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun 358:79\u201384","journal-title":"Biochem Biophys Res Commun"},{"key":"487_CR32","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1349-7006.2006.00300.x","volume":"97","author":"K Mutoh","year":"2006","unstructured":"Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y (2006) Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 97:1198\u20131204","journal-title":"Cancer Sci"},{"key":"487_CR33","first-page":"1327","volume":"1","author":"A Kanzaki","year":"2002","unstructured":"Kanzaki A, Takebayashi Y, Ren XQ, Miyashita H, Mori S, Akiyama S, Pommier Y (2002) Overcoming multidrug drug resistance in P-glycoprotein\/MDR1-overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 1:1327\u20131334","journal-title":"Mol Cancer Ther"},{"key":"487_CR34","first-page":"F756","volume":"270","author":"L Jett\u00e9","year":"1996","unstructured":"Jett\u00e9 L, Beaulieu E, Leclerc JM, B\u00e9liveau R (1996) Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 270:F756\u2013F765","journal-title":"Am J Physiol"},{"key":"487_CR35","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/S0021-9258(18)53865-5","volume":"268","author":"CE Herzog","year":"1993","unstructured":"Herzog CE, Tsokos M, Bates SE, Fojo AT (1993) Increased mdr-1\/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 268:2946\u20132952","journal-title":"J Biol Chem"},{"key":"487_CR36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1046\/j.1440-1614.1999.00639.x","volume":"33","author":"NA Keks","year":"1999","unstructured":"Keks NA, Altson K, Hope J, Krapivensky N, Culhane C, Tanaghow A, Doherty P, Bootle A (1999) Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 33:896\u2013901","journal-title":"Aust N Z J Psychiatry"},{"key":"487_CR37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","volume":"71","author":"DW Boulton","year":"2002","unstructured":"Boulton DW, DeVane CL, Liston HL, Markowitz JS (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71:163\u2013169","journal-title":"Life Sci"},{"key":"487_CR38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0924-8579(00)00199-0","volume":"16","author":"MV Bettencourt","year":"2000","unstructured":"Bettencourt MV, Bosne-David S, Amaral L (2000) Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 16:69\u201371","journal-title":"Int J Antimicrob Agents"},{"key":"487_CR39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","volume":"187","author":"JS Wang","year":"2006","unstructured":"Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL (2006) Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 187:415\u2013423","journal-title":"Psychopharmacology (Berl)"},{"key":"487_CR40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.pnpbp.2004.11.022","volume":"29","author":"T Masui","year":"2005","unstructured":"Masui T, Kusumi I, Takahashi Y, Koyama T (2005) Efficacy of carbamazepine against neuroleptic-induced akathisia in treatment with perospirone: case series. Prog Neuropsychopharmacol Biol Psychiatry 29:343\u2013346","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0487-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-008-0487-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0487-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T12:30:25Z","timestamp":1631277025000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-008-0487-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,14]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["487"],"URL":"https:\/\/doi.org\/10.1007\/s00228-008-0487-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,14]]}}}